Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01639248
Title Phase 2 Study - Aurora + Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced + Metastatic TNBC
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements No
Sponsors CASI Pharmaceuticals, Inc.
Indications

triple-receptor negative breast cancer

Therapies

ENMD-2076

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.